Key statistics
On Monday, Amylyx Pharmaceuticals Inc (AMLX:NSQ) closed at 6.41, -11.83% below its 52-week high of 7.27, set on Nov 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.34 |
---|---|
High | 6.57 |
Low | 6.26 |
Bid | 6.41 |
Offer | 6.49 |
Previous close | 6.33 |
Average volume | 3.19m |
---|---|
Shares outstanding | 89.14m |
Free float | 54.27m |
P/E (TTM) | -- |
Market cap | 564.26m USD |
EPS (TTM) | -3.10 USD |
Data delayed at least 15 minutes, as of Jun 30 2025 21:00 BST.
More ▼
- Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
- Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences
- Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome
- Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
- Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences
- Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
- Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia
- Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis
- Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
More ▼